Docetaxel and Gemcitabine Modulate Cellular Effects and Long Non-Coding RNA Profiles in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Lung cancer is a leading cause of cancer-related mortality globally.
• Current guidelines suggest gemcitabine (GEM) or docetaxel (DOC) monotherapy for specific non-small cell lung cancer (NSCLC) patient groups.
• Understanding the cellular mechanisms of these chemotherapeutics is crucial for optimizing treatment.

Purpose of the Study:

• To investigate the distinct cellular effects of GEM and DOC as monotherapies in various NSCLC cell lines.
• To analyze the impact of GEM and DOC on apoptosis, migration, cell cycle, autophagy, and long non-coding RNA (lncRNA) expression.
• To provide insights into the pharmacodynamic actions of GEM and DOC in NSCLC.

Main Methods:

• Utilized NSCLC cell lines including lung adenocarcinoma (A549, CALU6) and lung squamous cell carcinoma (LUSC, H520, H1703).
• Assessed cellular effects including apoptotic cell death, cell migration (scratch assay), cell cycle arrest, and autophagic activity.
• Analyzed the expression of key lncRNAs (MALAT1, NEAT1, HOTAIR) in response to GEM and DOC treatment.

Main Results:

• GEM and DOC induced apoptotic cell death in all tested NSCLC cell lines within 48 hours.
• Both chemotherapeutics affected cancer cell migration and induced distinct cell cycle arrest patterns.
• GEM and DOC triggered autophagic signals in LUSC lines, with GEM also showing effects in CALU6.
• Variable expression of MALAT1, NEAT1, and HOTAIR was observed in response to GEM and DOC.

Conclusions:

• GEM and DOC exhibit differential cellular effects in NSCLC models.
• These chemotherapeutics influence fundamental cancer processes like apoptosis, migration, and cell cycle progression.
• The study highlights the potential of GEM and DOC to modulate lncRNA expression, suggesting novel therapeutic avenues.